Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors

• Main Authors: Laura L. Meijer, Jisce R. Puik, Tessa Y.S. Le Large, Michal Heger, Frederike Dijk, Niccola Funel, Thomas Wurdinger, Ingrid Garajová, Nicole C.T. van Grieken, Mark A. van de Wiel, Elisa Giovannetti, Geert Kazemier
• Format: Article
• Language: English
• Published: MDPI AG 2019-08-01
• Series: Cancers
• Subjects: biliary tract cancer; distal cholangiocarcinoma; pancreatic cancer; diagnosis; biomarkers
• Online Access: https://www.mdpi.com/2072-6694/11/8/1181

Accurate diagnosis of pancreatic head lesions remains challenging as no minimally invasive biomarkers are available to discriminate distal cholangiocarcinoma (CCA) from pancreatic ductal adenocarcinoma (PDAC). The aim of this study is to identify specific circulating microRNAs (miRNAs) to diagnose distal CCA. In the discovery phase, PCR profiling of 752 miRNAs was performed on fourteen patients with distal CCA and age- and sex-matched healthy controls. Candidate miRNAs were selected for evaluation and validation by RT-qPCR in an independent cohort of distal CCA (<i>N</i> = 24), healthy controls (<i>N</i> = 32), benign diseases (<i>N</i> = 20), and PDAC (<i>N</i> = 24). The optimal diagnostic combination of miRNAs was determined by multivariate logistic regression analysis and evaluated by ROC curves with AUC values. The discovery phase revealed 19 significantly dysregulated miRNAs, of which six were validated in the evaluation phase. The validation phase confirmed downregulated miR-16 in patients with distal CCA compared to benign disease or PDAC (<i>P</i> = 0.048 and <i>P</i> = 0.012), while miR-877 was significantly upregulated (<i>P</i> = 0.003 and <i>P</i> = 0.006). This two-miRNA panel was validated as a CCA-specific profile, discriminating distal CCA from benign disease (AUC = 0.90) and from PDAC (AUC = 0.88). In conclusion, the present study identified a two-miRNA panel of downregulated miR-16 and upregulated miR-877 with promising capability to diagnose patients with distal CCA.